Today: 7 February 2026
Subscribe
Browse Category

FDA Updates News 19 December 2025 - 27 December 2025

Merck Stock (MRK) News and Forecasts: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Cidara Acquisition in Focus Ahead of the Next Market Session

Merck Stock (MRK) News and Forecasts: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Cidara Acquisition in Focus Ahead of the Next Market Session

As of 2:34 a.m. ET in New York on Saturday, December 27, 2025, U.S. stock markets are closed for the weekend.Merck & Co., Inc. (NYSE: MRK) was last quoted around $106.78, up about 0.33% versus its prior close, based on the latest available pricing feed. With year-end trading under way and liquidity often thinner around the holidays, Merck is heading into the next session with an unusually packed headline stack: policy-driven drug pricing news, FDA review acceleration for two experimental therapies, and portfolio diversification via M&A—all against the backdrop of investors constantly re-litigating the same big question: how Merck replaces
27 December 2025
······
FDA Frozen Shrimp Recall Over Cesium-137: Market 32 and Waterfront Bistro Products Pulled Across 17 States

FDA Frozen Shrimp Recall Over Cesium-137: Market 32 and Waterfront Bistro Products Pulled Across 17 States

Dec. 25, 2025 — If shrimp cocktail, shrimp scampi, or a quick freezer-to-pan seafood dinner is part of your holiday week, check your freezer before you cook. A new FDA-posted recall involves about 83,800 bags of frozen raw shrimp that may have been exposed to cesium-137 (Cs‑137), a man-made radioactive isotope. The recalled shrimp was imported from Indonesia and distributed in the U.S. under Market 32 and Waterfront Bistro labels by Direct Source Seafood LLC of Bellevue, Washington, according to federal and company recall notices. U.S. Food and Drug Administration The FDA and the company stress that this recall is
25 December 2025
Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics, Inc. (NASDAQ: TVTX) is ending 2025 with a bang. In the holiday-shortened U.S. trading session on Wednesday, December 24, 2025, TVTX surged sharply—pushing to fresh highs as investors recalibrated around two big themes: accelerating commercial execution for FILSPARI (sparsentan) and a looming FDA decision that could expand the drug into a second major kidney disease indication. StockAnalysis+2New York Stock Exchange+2 TVTX stock action on Dec. 24, 2025: a thin-session breakout with big numbers In early trading on Dec. 24, TVTX was up roughly 15% and changing hands around the low $40 range—an outsized move for a single session,
24 December 2025
·····
Merck (MRK) Stock News and Forecasts for Dec. 23, 2025: TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Wall Street’s Latest Targets

Merck (MRK) Stock News and Forecasts for Dec. 23, 2025: TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Wall Street’s Latest Targets

Merck & Co., Inc. (NYSE: MRK) is closing in on year-end with a rare mix of policy-driven headlines, regulatory acceleration, and pipeline catalysts that are shaping investor expectations for 2026 and beyond. From a White House-backed drug-pricing framework that offers tariff relief to drugmakers, to the FDA’s fast-track voucher program attaching itself to two Merck assets with blockbuster potential, MRK stock is being evaluated not just on quarterly numbers—but on whether Merck can extend growth beyond Keytruda while navigating intensifying U.S. drug-pricing scrutiny. Reuters+2Reuters+2 Below is a comprehensive, publication-ready roundup of today’s MRK stock action, the key news moving the
23 December 2025
·····
GSK Stock News Today (Dec. 23, 2025): Buyback Update, Director Buying, US Drug-Pricing Deal, and FDA Wins — What Analysts Forecast Next

GSK Stock News Today (Dec. 23, 2025): Buyback Update, Director Buying, US Drug-Pricing Deal, and FDA Wins — What Analysts Forecast Next

GSK plc stock is ending 2025 with a dense cluster of catalysts—some bullish, some complicated, and all very “big pharma in an election-year policy blender.” Early Tuesday (Dec. 23, 2025), GSK’s ADR (NYSE: GSK) traded around $48.59, essentially flat on the session. Yahoo FinanceBehind that quiet tape, the company has been filing fresh buyback disclosures, reporting director share purchases, and navigating new US drug-pricing agreements—while continuing to stack up regulatory wins across respiratory and infectious disease. Below is what’s driving the GSK stock narrative right now, and how the latest forecasts and analyst views frame the next leg. What’s new
23 December 2025
·····
Johnson & Johnson Stock (JNJ) Before the Market Opens on December 22, 2025: FDA Catalysts, Talc Litigation Headlines, Analyst Targets, and What to Watch

Johnson & Johnson Stock (JNJ) Before the Market Opens on December 22, 2025: FDA Catalysts, Talc Litigation Headlines, Analyst Targets, and What to Watch

Johnson & Johnson (NYSE: JNJ) heads into the U.S. market open on Monday, December 22, 2025, with investors balancing a familiar mix of defensive-healthcare appeal and headline-driven catalysts—from fresh talc litigation verdicts to FDA-related momentum in oncology and MedTech. Below is what matters most for JNJ stock right now, what analysts are projecting, and which near-term triggers could move shares as the holiday week begins. JNJ stock price check: where shares stand heading into December 22 As of the latest available pricing from the most recent session (Friday, December 19), Johnson & Johnson stock traded around $206.37. The session’s trading
22 December 2025
·····
Philip Morris International (PM) Stock Week Ahead: Dividend Watch, FDA Nicotine Pouch Developments, Analyst Targets and Key Catalysts for Dec. 22–26, 2025

Philip Morris International (PM) Stock Week Ahead: Dividend Watch, FDA Nicotine Pouch Developments, Analyst Targets and Key Catalysts for Dec. 22–26, 2025

Published: Sunday, Dec. 21, 2025 (week-ahead outlook) Philip Morris International Inc. (NYSE: PM) heads into the Christmas-shortened trading week with a familiar mix of forces: a defensive consumer-staples profile, an income-driven shareholder base watching the next dividend milestone, and an evolving regulatory backdrop for nicotine pouches and other smoke-free products. PM shares last closed around $156.84 (Friday close), sitting well below the 2025 peak but still far above the year’s lows—an important context as liquidity thins into the holiday. FT Markets Below is what matters most for PM stock in the week ahead (Dec. 22–26, 2025): the trading calendar, PMI-specific
21 December 2025
·····
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered around Dec. 19–21, 2025. From the White House’s sweeping “most-favored-nation” (MFN) push on U.S. drug prices to BioMarin’s largest-ever acquisition and fresh FDA approvals, the setup into year-end has become more headline-sensitive than the calendar would suggest. Here’s what investors and traders should be watching in pharma stocks in the week ahead. Christmas week trading: shorter sessions, fewer buyers, faster
21 December 2025
···········
Philip Morris International (PM) Stock News Today: Dividend, FDA Catalysts, and Wall Street Forecasts as of Dec. 20, 2025

Philip Morris International (PM) Stock News Today: Dividend, FDA Catalysts, and Wall Street Forecasts as of Dec. 20, 2025

Updated: December 20, 2025 — Philip Morris International Inc. (NYSE: PM) stock is ending the week in the spotlight as investors balance a resilient dividend story with a fast-moving U.S. “smoke-free” growth narrative built around ZYN nicotine pouches and the IQOS heated-tobacco platform. While U.S. markets are closed on Saturday, the latest available quote (from Friday’s session) puts PM at $156.84 at the close, with modest after-hours strength. StockAnalysis What’s driving attention now isn’t just day-to-day price action—it’s the convergence of near-term catalysts (an upcoming FDA scientific advisory committee meeting tied to modified-risk claims for ZYN) and longer-term questions (how
20 December 2025
····
Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next

Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next

Disc Medicine, Inc. (NASDAQ: IRON) stock is seeing a classic “biotech catalyst storm” on Dec. 20, 2025: big intraday swings, headline-driven volatility, and analysts arguing over whether the market is repricing risk or merely repricing uncertainty. As of the latest trading data available, IRON was around $80.04, down roughly 11.5% versus the prior close, after trading as high as $94.60 and as low as $71.46 on heavy volume (about 4.22 million shares). The immediate trigger: a report-driven debate about the FDA’s new fast-track voucher process and whether Disc’s lead drug candidate, bitopertin, remains on the clean, accelerated path bulls were
20 December 2025
·····
Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen

Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen

Merck & Co., Inc. (NYSE: MRK) finished Friday’s regular session (Dec. 19, 2025) modestly higher, then eased slightly in after-hours trading as investors digested a headline-heavy day featuring U.S. drug-pricing policy moves and FDA acceleration for two major Merck pipeline assets. Below is what happened after the bell, why it matters, and the key items to track before the next U.S. market open (Monday, Dec. 22, 2025). MRK stock price after the bell: the key numbers Merck shares closed at $101.09, up $0.40 (+0.40%) on Friday. Zacks+1 In after-hours trading, MRK was slightly lower, trading around $100.9–$101.0 in early evening
20 December 2025
·····
Johnson & Johnson Stock News Today (Dec. 19, 2025): Trump Drug-Price Deals, FDA Wins and Fresh $240 Targets Put JNJ in Focus

Johnson & Johnson Stock News Today (Dec. 19, 2025): Trump Drug-Price Deals, FDA Wins and Fresh $240 Targets Put JNJ in Focus

Johnson & Johnson (NYSE: JNJ) is back on investors’ radar on Friday, December 19, 2025, as Wall Street digests a fast-moving mix of Washington drug-pricing headlines, a string of U.S. FDA decisions across pharma and medtech, ongoing talc litigation, and a wave of updated analyst price targets. JNJ shares traded around $208 intraday, hovering near the flatline as the market weighed policy risk against company-specific catalysts. MarketScreener Below is what’s driving the Johnson & Johnson stock narrative today—and what investors will be watching next. Why Johnson & Johnson stock is in the spotlight on Dec. 19, 2025 1) Drug-pricing pressure
19 December 2025
·····
1 2 3 4 5 6

Stock Market Today

Diageo share price slips into the weekend as investors eye Feb. 25 results

Diageo share price slips into the weekend as investors eye Feb. 25 results

7 February 2026
Diageo shares closed down 1.48% at 1,760 pence on Friday, trailing a 0.59% gain in the FTSE 100. An updated analyst consensus points to a 2.0% fall in first-half organic net sales ahead of interim results due Feb. 25. Trading volume was light, and the stock remains over 22% below its 52-week high.
National Grid share price: what to know before London reopens after BoE signal

National Grid share price: what to know before London reopens after BoE signal

7 February 2026
National Grid shares closed at 1,285 pence in London on Friday, up 0.23%. The Bank of England held rates at 3.75% after a close vote, signaling possible cuts if inflation falls. National Grid announced a wireless power transmission study with Space Solar and marked five years of IFA2 interconnector operations. Its U.S. ADR ended at $88.06, up $1.17.
BAE Systems share price rises into weekend — what to watch before Monday’s London open

BAE Systems share price rises into weekend — what to watch before Monday’s London open

7 February 2026
BAE Systems shares closed up 1.2% at 1,879 pence on Friday, tracking gains in European defence stocks. The company’s market value stands near £54.8 billion. Investors await BAE’s full-year results on Feb. 18 for updates on cash returns and orders. GXO Logistics renewed and expanded its contract to support BAE’s Type 26 frigate program in Scotland.
Go toTop